undamentalytics Newsletter
Sign in

Biote Corp. revenue

Biote Corp.'s revenue was $192m in fiscal 2025, down 2.5% on the year before. Since fiscal 2021 ($139m) it has grown at a compound 8.4% a year. Over the last twelve months it was $184m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue139165185197192184
Growth on the year before—+18.3%+12.4%+6.4%−2.5%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Product Revenue $187M 97.5% ▼ 2.8%
Pellet Procedures Product Revenue $137M 73.3% ▼ 8.8%
Dietary Supplements $42.9M 22.9% ▲ 19.1%
Service Revenue $5.3M 2.8% ▲ 6.9%
Shipping Fees and Other Product Revenue $2.1M 1.2% ▲ 38.9%
Disposable Trocars Product Revenue $4.9M 2.5% ▲ 11.7%

From Biote Corp.'s 10-K filed March 13, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Biote Corp. $184m -7.8% 0.5%
Organigram Global Inc. $185m 57.8% —
Kamada LTD $180m 12.1% —
Cronos Group Inc. $179m 37.5% 30.3%
Amarin Corp plc\uk $176m -22.3% -18.3%
Heron Therapeutics, Inc. $151m 1.0% 8.6%

Compare with peers

Head to head: BTMD vs OGIBTMD vs KMDABTMD vs CRONAMRN vs BTMD

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Biote Corp.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biote Corp.